Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
Purpose: Sunitinib and pazopanib are multitargeted tyrosine kinase inhibitors (TKIs) that act against vascular endothelial growth factor receptors and are standard first-line treatment options for metastatic clear cell renal cell carcinoma (ccRCC). The Brazilian public health system diverges from th...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2018-09-01
|
Series: | Journal of Global Oncology |
Online Access: | http://ascopubs.org/doi/10.1200/JGO.18.00073 |